Position in ROIV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,775,736
-$5,631,645 QoQ
Shares Held
64,106
-81.2% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.47%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Neo Ivy Capital Management holds $22,354,354 across 16 Biotechnology names. ROIV ranks #7 (7.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DYN |
Dyne Therapeutics, Inc.
|
168,753 | $3,059,491 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
186,172 | $2,692,047 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
43,355 | $2,449,123 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
27,033 | $2,251,578 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
60,833 | $2,020,872 | |
| 6 | ADMA |
Adma Biologics, Inc.
|
199,687 | $1,799,179 | |
| 7 | ROIV |
Roivant Sciences Ltd.
This page
|
64,106 | $1,775,736 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
73,601 | $1,541,940 |
All Filings in ROIV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,775,736 | 64,106 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $7,407,381 | 341,354 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $3,591,740 | 237,392 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $811,778 | 72,030 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||